As the incidence of calcific aortic valve stenosis increases with the aging of the population, improved understanding and novel therapies to reduce its progression and need for aortic valve replacement are urgently needed.
INTRODUCTION
Calcific aortic valve stenosis is a progressively debilitating and potentially fatal disease that is currently treated with surgical aortic valve replacement (AVR) in patients who can tolerate surgery or with transcatheter AVR in those with high surgical risk. It is estimated that there are over 1 million patients with aortic valve stenosis in the United States and over 2.5 million worldwide [1] . Affected aortic valve leaflets are characterized by progressive fibrosis, thickening, and most importantly, calcification [2,3 && ], resulting in decreased leaflet mobility and increased obstruction of blood outflow from the left ventricle. Progressive worsening of aortic valve stenosis occurs in the majority of patients, eventually leading to symptoms, such as angina, syncope, and heart failure requiring AVR. Approximately 50% of patients are not eligible for AVR because of co-morbidities, and generally develop progressive heart failure and death. Effective medical therapies do not exist, and statins have failed to reduce progression of AVR in four randomized trials [4] [5] [6] [7] . Novel therapies to reduce the progression of aortic valve stenosis are urgently needed, because as the population ages there will be a corresponding progressive increase in incidence and prevalence of aortic valve stenosis. We review the literature examining the role of lipoprotein(a) [Lp(a)] as a risk factor for aortic valve stenosis in clinical studies, as well as evidence describing the mechanisms by which its oxidized phospholipids (OxPL) content may mediate progression of aortic valve stenosis.
LIPOPROTEIN(a) IS A RISK FACTOR FOR AORTIC VALVE STENOSIS

Epidemiology studies
Lp(a) was initially identified as a risk factor for aortic valve disease based on the results of several epidemiologic and observational studies (summarized in Table 1 ). Cross-sectional studies [8, 9] have found enrichment of individuals with elevated Lp(a) in those diagnosed with aortic valve sclerosis or stenosis by echocardiography. Case-control studies revealed that elevated Lp(a) was an independent risk factor for aortic valve stenosis among patients who had AVR [10] and for aortic valve calcification in consecutive patients who had outpatient echocardiograms [11] . Data from the Copenhagen City Heart Study (CCHS) and the Copenhagen General Population Study (CGPS) showed an observational hazard ratio of aortic stenosis of 1.4 [95% confidence interval (CI) 1.2-1.7] for a 10-fold increase in Lp(a) plasma levels [12 & ]. Another analysis of the same cohorts examined both causal and observational associations between aortic valve stenosis and Lp(a), and reported an observational hazard ratio
KEY POINTS
Lp(a) is a genetically determined, causal, independent risk factor for calcific aortic valve stenosis.
Lp(a) is the major lipoprotein carrier of OxPL, a set of bioactive lipids which likely contribute to aortic valve inflammation and calcification in aortic valve stenosis.
Elevated Lp(a) (>58.5 mg/dl) and OxPL-apoB (>5.50 nM) levels predict faster rate of progression of aortic valve stenosis and need for AVR.
Statins, which may raise plasma Lp(a) and OxPL-apoB, have not been shown to alter the natural progression of aortic valve stenosis in clinical trials.
Antisense oligonucleotides targeted to apo(a) potently reduce Lp(a) and OxPL-apoB levels and can be tested to reduce the progression of aortic valve stenosis and need for AVR. ]. In summary, multiple epidemiological studies provide strong support that elevated Lp(a) levels are associated with aortic valve stenosis. Epidemiologically, the risk of aortic valve stenosis seems to start at Lp(a) levels of $30 mg/dl ($75 nmol/l), but substantial risk does not accrue until Lp(a) levels are approximately greater than 60 mg/dl ($>150 nmol/l).
Genetic studies
Apart from epidemiologic studies describing a relationship between Lp(a) and aortic valve stenosis, a genetically determined relationship exists between Lp(a) levels and calcific aortic valve disease (summarized in Table 2 ). The single nucleotide polymorphism (SNP) rs10455872 in the gene LPA, encoding for apo(a), was found in a Genome Wide Association Study (GWAS) to be strongly linked to aortic valve calcification as determined by computed tomography (CT). This finding was reported by the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) consortium using data, in the discovery phase of their analysis, from three large cohorts: The Framingham Heart Study (FHS), the Age, Gene/Environment Susceptibility-Reykjavik Study (AGES-RS), and white European participants from the Multi-Ethnic Study of Atherosclerosis (MESA), a total of 6942 participants. After multivariate adjustments, the SNP rs10455872 [risk allele (G)] was associated with an increased risk of aortic valve calcium with an OR of 2.05 (CI 1.63-2.57). Mendelian randomization analysis within the same study demonstrated that the LPA SNP rs10455872, associated with elevated plasma Lp(a) and aortic valve calcification in whites and blacks, was a genetically determined risk factor for aortic valve calcification [OR 1.62 (CI 0.94-2.81) per log-nmol/l increase in Lp(a)] and that this risk was likely mediated by the biological activity of Lp(a). Using data from the Malmö Diet and Cancer Study (MDCS) (n ¼ 28 193) and CCHS (n ¼ 10 400), an independent association between rs10455872 and incident aortic valve stenosis was also demonstrated, with a hazard ratio of 1.68 (CI 1.32-2.15) per risk allele reported for the MDCS cohort and a hazard ratio of 1.6 (CI 1.12-2.28) for the presence of at least one risk allele reported for the CCHS cohort. Importantly, additional analysis demonstrated that the association of rs10455872 with aortic valve calcium was independent of coronary artery calcium and clinical coronary artery disease [17] .
A Mendelian randomization analysis with LPA SNPs was performed using clinical data containing individual diagnoses for aortic valve stenosis from the CGPS and CCHS (n ¼ 77 680). Median Lp(a) levels varied with SNP rs10455872 carrier status (11 mg/dl or $27.5 nmol/l for noncarriers, 60 mg/ dl or $150 nmol/l for heterozygotes, and 108 mg/dl or $270 nmol/l for homozygotes). Lp(a) levels were also increased in carriers of SNP rs3798220 and with decreasing numbers of LPA kringle IV type 2 (KIV-2) repeats. Carriers of SNP rs10455872 had a multivariable adjusted hazard ratio of 1.6 (CI 1.2-2.0) for heterozygotes and 1.5 (CI 0.5-4.8) for homozygotes (trend, P < 0.001) compared with noncarriers. The rs3798220 SNP was also associated with elevated Lp(a), but its prevalence was too low to rule out whether an association was also present with aortic valve stenosis. When including all LPA genotypes (i.e., rs10455872, rs3798220, and KIV-2 percentile group), the authors reported a relative risk of aortic valve stenosis of 1.6 (CI 1.2-2.1) for a 10-fold increase in genetically determined Lp(a) values [12 & ]. Using a multidirectional Mendelian randomization design, a study with 100 578 patients reported a causal risk ratio for aortic valve stenosis of 1.38 (CI 1.23-1.55) for each SD increase in Lp(a) based on LPA SNPs (rs10455872 and rs3798220) and 1.21 (CI 1.06-1.40) for each SD increase in Lp(a) associated with LPA KIV-2 genotype [13] . Within the EPIC-Norfolk study (n ¼ 17 553) described above, carriers with one rs10455872 G allele had an unadjusted hazard ratio for aortic valve stenosis of 1.78 (CI 1.11-2.87), and those with two G alleles had an unadjusted hazard ratio for aortic valve stenosis of 4.83 (CI 1. 77-13.20) , compared with noncarriers [14] .
In summary, nine unique clinical studies demonstrated the predictive value of Lp(a) towards risk of developing aortic valve stenosis, and four large genetic studies using Mendelian randomization demonstrated that Lp(a) is a genetically determined, and therefore likely causal, mediator of aortic valve stenosis. With this in mind, reduction of Lp(a) concentrations, unlike reduction of LDL-C with statins, is a promising novel therapeutic approach for aortic valve stenosis.
STATINS AND LIPOPROTEIN(a)
Though LDL-C is also a risk factor for aortic valve stenosis, LDL-C lowering by statins has not been successful in altering the natural history of the disease. A recent Mendelian randomization analysis of 6942 patients from the CHARGE consortium and the MDCS demonstrated that a higher LDL-C genetic risk score (GRS), consisting of SNPs specifically associated with LDL-C and weighed by each SNP's correlation to plasma LDL-C levels, was associated with increased risk of incident aortic valve stenosis [18] . Although the LDL-C GRS did not correlate with Lp(a) mass, all conventional 'LDL-C' measurements include the content of Lp(a)-cholesterol (Lp(a)-C), which can be 30-45% of Lp(a) mass [19] , and may be a confounding variable in this analysis. Despite the role of LDL-C as a risk factor for aortic valve stenosis, and a small (n ¼ 121) openlabel trial demonstrating reduced progression of aortic valve stenosis in patients treated with rosuvastatin [20] , four randomized placebo-controlled LDL-C lowering trials have been conducted in well-established aortic valve stenosis with rosuvastatin (ASTRONOMER [6] and Tyrolean Aortic Stenosis Study (TASS) [20] ), atorvastatin (Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) [4] ), and simvastatin/ezetimibe (Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) [5] ). These collectively enrolled 2344 patients aged 58-68 years with mild to moderate aortic valve stenosis (ASTRONOMER, TASS, and SEAS) or moderate to severe aortic valve stenosis (SALTIRE), and all failed to show reduction in aortic valve stenosis progression [21] .
One possible explanation for the ineffectiveness of statins in these well-conducted trials is that LDL-C lowering must be initiated at an earlier age or stage of the disease (i.e., aortic sclerosis) in order to prevent aortic valve stenosis [22] . However, it is also likely that Lp(a), instead of LDL-C, is the major modifiable risk factor in aortic valve stenosis. Using the latter paradigm, it is not surprising that statins were not beneficial for aortic valve stenosis. Lp(a), compared with LDL, is relatively refractory to statin therapy. The LPA SNP rs10455872, which is associated with higher Lp(a) levels, has been associated with poorer response to LDL-C lowering by statins [23] [24] [25] . As the Lp(a) mass rises, the contribution of Lp(a)-C to measured LDL-C also increases [19] ; therefore, Lp(a) represents a pool of 'LDL-C' which is resistant to statin therapy and contributes to aortic valve stenosis risk, and can confound interpretation of aortic valve stenosis risk because of LDL-C. Studies on the precise effects of statins on Lp(a) are controversial, with differences in assay quality compromising the ability to perform robust meta-analyses [26, 27] . In certain statin trials, including those with rosuvastatin, atorvastatin, pravastatin, pitavastatin, and simvastatin/ezetimibe, Lp(a) increases 10-20% with statin therapy [28] (Fig. 1) . Specifically, in the ASTRONOMER trial, Lp(a) increased by 20% (P < 0.05) from baseline levels in the 112 out of 220 patients randomized to rosuvastatin and treated for 1 year [16 && ]. Lp(a) increased by 23% (P < 0.01) from baseline levels in hyperlipidemic patients treated with simvastatin/ezetimibe [28] , which was also the therapeutic intervention studied in SEAS [5] . These findings suggest that the benefits of LDL-C lowering by statins towards aortic stenosis may be offset by a deleterious increase in Lp(a).
MECHANISMS FOR LIPOPROTEIN(a) AND OXIDIZED PHOSPHOLIPIDS TOWARDS AORTIC VALVE CALCIFICATION AND THE PATHOGENESIS OF AORTIC VALVE STENOSIS
Early lesions on aortic valve leaflets in aortic valve stenosis contain oxidized lipids, apoB and apo(a), [28] . Refer to [28] for full citations on the studies described in this figure. macrophages, and T-cells [29] [30] [31] [32] . Apo(a), via its lysine binding domains, can bind to fibrin on denuded or injured endothelium [33] [34] [35] , such as that on aortic valves subjected to mechanical stress in vivo, as a likely mechanism for intravasation of Lp(a) into the valve. Thereafter, OxPL present on Lp(a) can mediate proinflammatory and pro-calcific pathways potentiating aortic valve stenosis (summarized in Fig. 2) .
OxPL are covalently bound to the apo(a) moiety of Lp(a), but are also present in the lipid phase of the particle [36] . In humans, more than 85% of plasma lipoprotein-associated OxPL are bound to Lp(a), whereas the remainder exist primarily on apoBcontaining lipoproteins [37] [38] [39] . A second large and independent pool of OxPL present on other proteins is covalently linked to plasminogen, which has no other lipid content [40, 41] . Consistently with the role of this apoB-100-containing lipoprotein as the preferential lipoprotein carrier of OxPL, OxPL on plasma apoB (OxPL-apoB) levels correlate with Lp(a) levels in the population as a whole. However, this is dependent on genetics and underlying apo(a) isoform composition, irrespective of race [42] [43] [44] [45] . Further genetic evidence that Lp(a) levels determine plasma OxPL levels include the high genetic covariance of Lp(a) and OxPL-apoB in a study examining these parameters in monozygotic vs. dizygotic twins [43] , and that the LPA SNPs rs3798220 [45] and rs10455872 [43] are also associated with elevated levels. Lastly, in trials with pharmacologic [16 && ,38,46-49] or dietary [50] [51] [52] interventions that raise Lp(a), OxPL-apoB is increased as well. Conversely, lipid apheresis [37] and antisense oligonucleotides (ASO) to apo(a) [53] and niacin [28] all lower OxPL-apoB.
OxPL play a central role in the development of atherosclerosis, which shares a similar pathogenesis with aortic valve stenosis, particularly in proinflammatory pathways [54, 55] . Using E06, a monoclonal IgM natural antibody that binds to the phosphorylcholine (PC) head group of oxidized but not native PC-containing phospholipids [56] [57] [58] , we have developed and clinically validated an ELISA that detects OxPL on plasma apoB [57, 59] , which primarily detects OxPL on Lp(a). Because most of the OxPL in human plasma is bound to Lp(a), the OxPL-apoB assay thus detects the most inflammatory and atherogenic Lp(a). In over 40 publications, we have shown that elevated OxPL-apoB levels predict death/myocardial infarction (MI)/stroke in unselected populations followed prospectively [60, 61] , correlate with endothelial dysfunction and progression of coronary calcification [51, 62] , predict the progression of femoral/carotid disease [63] and coronary artery disease (CAD) [64] , and are elevated in patients with acute coronary syndrome [65] and following percutaneous coronary intervention [66] .
Oxidized lipoproteins, which are highly enriched in OxPL [67] [68] [69] , have been implicated in promoting inflammation, valvular ectopic calcification, and bone formation, features that are pronounced in severe aortic valve stenosis. Oxidized LDL (OxLDL) potentiates macrophage-derived reactive oxygen species (ROS) and cytokine production [including CXCL1, CXCL2, CCL9, CCL5, and interleukin-1b (IL-1b)] via toll-like receptors TLR-2/4 and nuclear factor-kB (NF-kB) signaling, leading to increased oxidative stress and inflammation that can accelerate aortic valve stenosis [70] [71] [72] [73] . Specifically, monocytes exposed to OxPL on apo(a) upregulate expression of the inflammatory cytokine IL-8 [74 & ]. Bone formation within the diseased aortic valve is driven by the differentiation of vascular cells into osteoblasts [29] via bone morphogenic protein (BMP) signaling and upregulation of osteoblastic transcription factors including RUNX2 and MSX2. BMP2 [69, [75] [76] [77] as well as RUNX2 [78] and MSX2 [79] expression in vascular cells, including aortic valve-derived vascular interstitial cells (VICs), are upregulated following exposure to OxLDL. OxLDL exposure also suppresses osteoprotegerin [80] , an inhibitor of vascular calcification via the RANK-L pathway [81, 82] . Finally, exposure to OxLDL in vitro stimulates extracellular matrix calcium deposition by vascular cells [78, 79, 83, 84] as well as upregulation of alkaline phosphatase (ALP) [67, 79, 83, 85, 86] , promoting mineralization.
Apart from OxPL, Lp(a) associated enzymes and lipids have been implicated in the pathogenesis of calcific aortic valve stenosis. Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ), enriched on Lp(a) [87] , hydrolyzes OxPL to yield a free-oxidized fatty acid and lysophosphatidylcholine (LPC). Lp-PLA 2 expression and activity levels are higher in mineralized aortic valves compared with controls [88] , and Lp-PLA 2 ]. These findings consistently support the role of Lp(a) as a vehicle for harmful substrates that promote aortic valve stenosis. Whether Lp(a), its associated OxPL, or its metabolites will be viable therapeutic targets to mitigate aortic valve stenosis remains to be determined.
LIPOPROTEIN(a) AND OXIDIZED PHOSPHOLIPIDS ARE ASSOCIATED WITH INCREASED AORTIC VALVE STENOSIS PROGRESSION
Elevated Lp(a) and OxPL-apoB were predictive of a worse outcome in the ASTRONOMER trial, originally designed to evaluate the role of rosuvastatin in preventing the progression of aortic valve stenosis in those with mild to moderate aortic valve stenosis followed for 3.5 years [6] . In a prospective analysis of 220/269 patients from the original cohort with baseline Lp(a) and OxPL-apoB measurements, those with the highest tertile of Lp(a) (>58.5 mg/dl or $146 nmol/l) had aortic valve stenosis which progressed approximately 1.5 times faster (average peak velocity AE SD) (0.26 AE 0.03 vs. 0.17 AE 0.02 m/s/year) ( Fig. 3) and had approximately two-fold increased risk of a composite outcome of AVR (n ¼ 47 in the cohort) and cardiac death (n ¼ 2 in the cohort) [16 && ]. This relationship was the same between individuals with tricuspid or bicuspid valves (consisting of 48% of patients in this trial), but the risk of high Lp(a) on aortic valve stenosis progression and AVR was more pronounced in those younger than 57 years of age. The risk of aortic valve stenosis progression conveyed by elevated Lp(a) levels in this cohort of patients starting out with mild to moderate disease actually more closely reflects individuals with moderate to severe aortic valve stenosis ( Fig. 3) . Of great relevance, those with the highest tertile of OxPL-apoB (>5.50 nM) as well as OxPL on apo(a) [OxPL-apo(a)] (>33.5 nM) had an increased risk of aortic valve stenosis progression and AVR that was nearly identical to those with the highest tertile of Lp(a), consistent with the thesis that OxPL carried by Lp(a) is responsible for the biological activity of the particle.
FUTURE DIRECTIONS
There is a growing body of literature describing the role of Lp(a) as a genetically determined, causal risk factor for aortic valve stenosis. However, two major questions linger: first, what are the precise mechanisms linking Lp(a) to progression of aortic valve stenosis? and second, will Lp(a) lowering attenuate aortic valve calcification and the progression of aortic valve stenosis?
We are only beginning to understand the mechanisms by which Lp(a) promotes the progression of aortic valve stenosis. The relative contributions of lipids associated with Lp(a) implicated in aortic valve stenosis, namely OxPL, LPC, and LPA, remain to be characterized. One approach towards this question would be to quantify and compare OxPL, LPC, and LPA levels in human stenotic aortic valves and from human aortic valves without significant disease (i.e., explanted hearts from patients undergoing cardiac transplant) using liquid chromatography-mass spectrophotometry (LC-MS). This could be complemented by quantification of OxPL, LPC, and LPA on purified plasma Lp(a) in comparison to other lipoproteins such as LDL, also feasible by LC-MS, from patients with aortic valve stenosis enrolled in long-term prospective studies tracking progression of the disease.
Whether Lp(a)-associated OxPL or its metabolites are directly responsible for calcific aortic valve stenosis can be tested in vivo using animal models. To date, the only animal models that develop clinically significant calcific aortic valve stenosis are aged transgenic mice on an apoB 100 only /LDLR À/À background, fed a high cholesterol diet [89 && ,90,91]. Based on these existing models, we have generated transgenic hyperlipidemic Lp(a) mice which express human apoB-100 and apo(a) on an apoB 100 only / LDLR À/À background [92] . These models, along with transgenic models resulting in varying OxPL and/or Lp(a) levels in plasma, may be useful in studying mechanisms of calcific aortic valve stenosis development and progression.
Trials evaluating the effect of Lp(a) lowering on aortic valve stenosis progression are currently underway. Niacin [93] , cholesterol ester transfer protein inhibitors such as anacetrapib [94] , and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors including alirocumab and evolocumab [19] all lower plasma Lp(a), though only moderately (by 20-40%), and have diverse metabolic effects, including alterations in LDL-C, high-density lipoprotein cholesterol, and triglycerides. Participants are currently being recruited for a randomized, double-blind placebo control led trial designed to assess the effect of extended release niacin (1.5-2 g/day) on aortic valve disease progression over 2 years in those more than 50 years and less than 85 years with aortic sclerosis or mild aortic valve stenosis and Lp(a) > 50 mg/dl ($125 nmol/l). The primary outcome is aortic valve calcium score progression by cardiac CT, although the rate of hemodynamic progression of aortic valve stenosis will be determined by echocardiography at 1 and 2 years [95] . ASO targeted against mRNA encoding apo(a) [IONIS-APO(a) Rx ] (previously called ISIS-APO(a) Rx ) specifically lowered Lp(a) and its associated OxPL by up to 89 and 93%, respectively, in a recent phase I trial [53] . Results from clinical trials in patients with existing aortic valve stenosis randomized to antisense to apo(a) or placebo will add valuable knowledge regarding the mechanism and role of Lp(a) and OxPL in aortic valve stenosis and the efficacy of this novel therapeutic approach.
CONCLUSION
Lp(a) is a prevalent, genetically determined causal risk factor for calcific aortic valve stenosis, and its proinflammatory and pro-calcific lipid cargo, including OxPL, is likely mechanistically linked to the development of calcific aortic valve stenosis. Elevated Lp(a) (>58.5 mg/dl or $146 nmol/l) and OxPL-apoB (>5.50 nM) levels predict faster rate of aortic valve stenosis progression as well as need for AVR. Whereas LDL-C lowering by statins has not been effective in altering the natural progression of aortic valve stenosis, trials with potent Lp(a) lowering therapies, including IONIS-APO(a)-L Rx , represent a promising novel therapeutic approach for aortic valve stenosis.
